Regulus Therapeutics Inc. (NASDAQ:RGLS) was the target of a significant growth in short interest during the month of July. As of July 31st, there was short interest totalling 3,628,475 shares, a growth of 50.2% from the July 14th total of 2,416,318 shares. Based on an average daily trading volume, of 1,275,335 shares, the short-interest ratio is presently 2.8 days. Approximately 4.7% of the shares of the company are short sold.

A number of analysts recently issued reports on the stock. Needham & Company LLC restated a “hold” rating on shares of Regulus Therapeutics in a report on Wednesday, August 2nd. Chardan Capital downgraded shares of Regulus Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, August 2nd. Wedbush restated an “ourperform” rating and set a $4.00 price objective on shares of Regulus Therapeutics in a report on Monday. Zacks Investment Research downgraded shares of Regulus Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, July 19th. Finally, BMO Capital Markets set a $1.00 price objective on shares of Regulus Therapeutics and gave the stock a “hold” rating in a report on Monday, June 12th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $3.58.

In related news, insider Joseph P. Hagan acquired 219,780 shares of the firm’s stock in a transaction that occurred on Tuesday, July 25th. The stock was acquired at an average price of $0.91 per share, for a total transaction of $199,999.80. Following the completion of the acquisition, the insider now owns 241,297 shares of the company’s stock, valued at approximately $219,580.27. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director William H. Rastetter acquired 274,725 shares of the firm’s stock in a transaction that occurred on Tuesday, July 25th. The shares were bought at an average price of $0.91 per share, with a total value of $249,999.75. The disclosure for this purchase can be found here. Insiders have purchased 549,450 shares of company stock valued at $500,000 in the last 90 days. 4.80% of the stock is currently owned by corporate insiders.

Several large investors have recently added to or reduced their stakes in RGLS. LMR Partners LLP acquired a new stake in Regulus Therapeutics during the second quarter valued at approximately $164,000. Wedbush Securities Inc. raised its stake in Regulus Therapeutics by 10.3% in the second quarter. Wedbush Securities Inc. now owns 199,521 shares of the biopharmaceutical company’s stock valued at $197,000 after buying an additional 18,600 shares during the last quarter. Tudor Investment Corp ET AL raised its stake in Regulus Therapeutics by 131.5% in the first quarter. Tudor Investment Corp ET AL now owns 108,061 shares of the biopharmaceutical company’s stock valued at $178,000 after buying an additional 61,373 shares during the last quarter. South Dakota Investment Council raised its stake in Regulus Therapeutics by 16.3% in the first quarter. South Dakota Investment Council now owns 1,327,058 shares of the biopharmaceutical company’s stock valued at $2,190,000 after buying an additional 186,130 shares during the last quarter. Finally, Wells Fargo & Company MN raised its stake in Regulus Therapeutics by 13.5% in the first quarter. Wells Fargo & Company MN now owns 782,380 shares of the biopharmaceutical company’s stock valued at $1,291,000 after buying an additional 93,295 shares during the last quarter. 21.09% of the stock is owned by hedge funds and other institutional investors.

Regulus Therapeutics (NASDAQ RGLS) opened at 0.8952 on Friday. Regulus Therapeutics has a 12 month low of $0.85 and a 12 month high of $3.68. The company’s market cap is $92.91 million. The firm’s 50-day moving average is $0.99 and its 200-day moving average is $1.30.

Regulus Therapeutics (NASDAQ:RGLS) last released its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.41) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.31) by $0.10. Regulus Therapeutics had a negative net margin of 31,460.47% and a negative return on equity of 173.20%. The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.02 million. On average, analysts anticipate that Regulus Therapeutics will post ($1.10) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another site, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/08/11/regulus-therapeutics-inc-rgls-short-interest-update-2.html.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.